# Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

> **NCT04466345** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 72 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **BIOLOGICAL:** Semaglutide
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04466345
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-06
- **Primary completion:** 2024-12-27
- **Final completion:** 2024-12-27
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04466345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04466345, "Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04466345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*